CASI Pharmaceuticals Inc is a holding company principally engaged in developing and commercializing innovative therapeutics and pharmaceutical products. The Companyâ€™s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Companyâ€™s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The Company mainly conducts its business in the domestic market.

Employees

214

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-08-18	US$0.1394	-5.81%	6,661
26-08-14	US$0.1480	+1.40%	840
26-08-13	US$0.1460	+10.66%	2,693
26-08-12	US$0.1319	+2.41%	1,154
26-08-11	US$0.1288	+7.33%	6,252

Real-time OTC Markets

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Real-time OTC Markets 10:57:58 2026-06-03 EDT			5-day change	1st Jan Change
0.1052 ^USD	-2.09%		-18.25%	-87.61%

Market Cap	2.87M 2.46M 2.3M 2.11M 3.96M 274M 4.03M 27.08M 10.61M 137M 10.76M 10.53M 454M	P/E 2024	-1.11x	P/E 2025	-0.33x
Enterprise Value	24.72M 21.2M 19.8M 18.17M 34.16M 2.36B 34.72M 234M 91.49M 1.18B 92.82M 90.8M 3.92B	EV / Sales 2024	1.75x	EV / Sales 2025	1.9x
Free-Float	53.62%	Yield 2024 *	-	Yield 2025	-

08-14	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
06-02	CASI Pharmaceuticals, Inc. Announces Resignation of Barbara Krebs-Pohl as Director, Effective May 31, 2026	CI
05-15	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-14	CASI Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
04-20	CASI Pharmaceuticals, Inc. announced that it has received $20 million in funding from ETP Global III Fund LP	CI
04-20	CASI Pharmaceuticals, Inc. Announces Termination of Dr. Alexander A. Zukiwski, MD as Global Chief Medical Officer, Effective April 20, 2026	CI
03-03	CASI Pharmaceuticals, Inc. Announces CEO Changes	CI
03-03	Casi Pharmaceuticals, Inc. Announces Resignation of Director David Cory, Effective March 31, 2026	CI

08-14	CASI Pharmaceuticals Announces First Half 2026 Business and Financial Results	AQ
07-01	CASI Pharmaceuticals : Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Active and Chronic Active Antibody-mediated Rejection	PU

1 day	-2.09%
1 week	-18.25%
Current month	-18.25%
1 month	-36.57%
3 months	-24.79%
6 months	-86.48%
Current year	-87.61%

CASI Pharmaceuticals, Inc. Stock

Stocks

CASIF

KYG1933S1012

Pharmaceuticals

Valuation: CASI Pharmaceuticals, Inc.

Chart: CASI Pharmaceuticals, Inc.

Latest news : CASI Pharmaceuticals, Inc.

Press Releases: CASI Pharmaceuticals, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: CASI Pharmaceuticals, Inc.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

1 week	0.11	0.16
1 month	0.11	0.17
Current year	0.05	1.2
1 year	0.05	2.59
3 years	0.05	8.48
5 years	0.05	17.4
10 years	0.05	88.92

Manager	Title	Age	Since
David Cory CEO	Chief Executive Officer	62	2025-07-20
Kun Qian DFI	Director of Finance/CFO	44	2025-05-15
Chun Hua Wang COO	Chief Operating Officer	54	2016-12-31

Director	Title	Age	Since
Yue Wu BRD	Director/Board Member	62	2013-03-31
Zhen Bo Su BRD	Director/Board Member	50	2023-03-20
Thomas Folinsbee BRD	Director/Board Member	59	2023-03-20

Date	Insider	Type	Main position	Quantity	% Market Cap.
3/18/26	Hai Huang	Other	Global Chief Commercial Ofcr	280,000	1.8073%
9/7/22	Alexander Zukiwski	Free	Chief Technology Officer	3,000	0.0220%
9/6/22	James Huang	Other	Chairman	0	0%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CASI PHARMACEUTICALS, INC.	-2.09%	-18.25%	-95.34%	-95.46%	2.87M
ELI LILLY AND COMPANY	+3.42%	+4.32%	+81.02%	+131.43%	1,093B
JOHNSON & JOHNSON	+0.46%	+4.46%	+53.26%	+62.83%	653B
ABBVIE INC.	+1.26%	+5.60%	+27.40%	+74.94%	458B
ROCHE HOLDING AG	+1.80%	+0.52%	+41.20%	+44.48%	355B
NOVARTIS AG	+1.24%	+2.35%	+25.99%	+41.24%	294B
ASTRAZENECA PLC	+2.07%	+2.97%	+2.27%	+12.89%	248B
AMGEN INC.	+2.62%	+4.83%	+47.62%	+67.35%	230B
NOVO NORDISK A/S	+1.05%	-0.02%	-13.96%	-52.51%	203B
GILEAD SCIENCES, INC.	+2.27%	+8.10%	+24.49%	+93.40%	178B
Average	+1.39%	+1.08%	+19.39%	+38.06%	371.05B
Weighted average by Cap.	+1.96%	+1.45%	+46.12%	+73.16%

	2024	2025
Net sales	28.54M 24.48M 22.86M 20.97M 39.44M 2.73B 40.09M 270M 106M 1.37B 107M 105M 4.52B	20.71M 17.77M 16.59M 15.22M 28.62M 1.98B 29.09M 196M 76.66M 993M 77.77M 76.08M 3.28B
Net income	-39.26M -33.68M -31.45M -28.85M -54.25M -3.75B -55.15M -371M -145M -1.88B -147M -144M -6.22B	-48.06M -41.22M -38.49M -35.32M -66.41M -4.59B -67.51M -454M -178M -2.3B -180M -177M -7.62B
Net Debt	6.05M 5.19M 4.85M 4.45M 8.36M 578M 8.5M 57.18M 22.39M 290M 22.72M 22.22M 959M	21.85M 18.75M 17.5M 16.06M 30.2M 2.09B 30.7M 207M 80.88M 1.05B 82.06M 80.27M 3.46B